Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

NCT03483103 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.

NCT NCT03483103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03483103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Phase
Phase 2
Overall status
Completed
Start date
July 27, 2018
Completion date
December 1, 2022
Enrollment
74 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell, lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin, lymphoma, nonhodgkin